| HOME >> BIOLOGY >> TECHNOLOGY |
Other tax payable 1,546 2,343
Other current liabilities 2,769 1,757
Total current liabilities: 36,402 30,594
Non-current liabilities:
Long-term debt, excluding current portion 5,252 5,763
Advanced subsidies 1,046 1,027
Convertible notes 41,818 0
Deferred tax liabilities 125 129
Total non-current liabilities 48,241 6,919
Total liabilities 84,643 37,513
Mezzanine equity 100,735 49,106
Shareholders' deficit:
Ordinary shares (Note 1), ($0.02 par
value, 550,000,000 authorized,
249,060,000 and 197,901,450 issued
and outstanding as of December 31,
2006 and June 30, 2007, respectively) 3,958 4,981
Additional paid-in capital 37,861 33,075
Retained earnings (accumulated deficit) (78,080) (40,173)
Accumulated other comprehensive income 3,129 1,549
Treasury stock (360) (360)
Total shareholders' deficit (33,492) (928)
Total liabilities, mezzanine
equity and shareholders' deficit 151,886 85,691
Note 1: Eight (8) ordinary shares are equal to one (1) ADS
WUXI PHARMATECH (CAYMAN) INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2007 AND 2006
(In thousands of US Dollars, except ADS data and per ADS data )
'/>"/>
| SOURCE WuXi PharmaTech (Cayman) Inc. Copyright©2007 PR Newswire. All rights reserved |